Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer - Seite 2
Dr Mario Polywka, Evotec's Interim Chief Executive Officer, added: "Dr Christian Wojczewski is an experienced healthcare industry executive with a long track record of establishing high performance teams, critical top and bottom-line focus, and strong customer orientation. I have full confidence in his ability to lead Evotec and its smart people into a bright future."
About Dr Christian Wojczewski
Dr Christian Wojczewski (52) holds a diploma and a doctorate in chemistry from the Johann Wolfgang Goethe University in Frankfurt am Main. From 2000, he worked as a manager at McKinsey for
companies in the pharmaceutical, biotech and chemical industries in Europe and the USA. In 2005, he joined Linde, the global market leader for medical and industrial gases. After various roles
within the company, Wojczewski took over as Head of Group Strategy in 2007. During this time, he was responsible, among other things, for the integration of both companies, the transformation into
a high-performance organisation and the strategic realignment of the Linde Group following the acquisition of BOC. After 2010, Wojczewski took over the management of Linde Healthcare, one of the
Group's key growth drivers. During this time, Linde Healthcare developed into the global market leader for medical gases and services for patients with chronic respiratory diseases. Under his
leadership, sales in a total of 60 countries tripled to more than € 3 bn with leading EBITDA margins within the group. In 2017, Wojczewski joined Mediq in the Netherlands, a European leader in
medical devices and related services. As group CEO, he led the strategic review of the portfolio, strengthened critical operating systems while streamlining business processes, and reinforced a
high-performance culture throughout the organisation. Through a realignment and transformation, Mediq under Wojczewski's leadership achieved an impressive turnaround with strong EBITDA recovery and
towards profitable growth. Most recently, Wojczewski has served as a senior advisor to investors and biotech companies.
Lesen Sie auch
ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The
Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class
pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as
other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious
diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary
and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's 17 sites offer highly synergistic
technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.